Comparative Pharmacology
Head-to-head clinical analysis: FLEXERIL versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXERIL versus PARAFON FORTE DSC.
FLEXERIL vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination